Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0299/2023

Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0299/2023

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - June 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 June 2024, 10:00 (CEST) to 26 June 2024, 12:00 (CEST)

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - June 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 June 2024, 10:00 (CEST) to 26 June 2024, 12:00 (CEST)

ESIM Winter 2025

Dear EFIM Members,

We are pleased to announce that the Swedish Society of Internal Medicine will be hosting the13th Winter School of the European School of Internal Medicine, in February from 9th– 15th 2025 in Björkliden, Sweden.

It will be the final edition for the Swedish Society hosting the winter School in Björkliden, Sweden, and as every year it will offer very active educational programme, bringing together residents from across Europe to advance knowledge, share best practices, and foster connections.

Human medicines European public assessment report (EPAR): Dzuveo, sufentanil, Date of authorisation: 25/06/2018, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Dzuveo, sufentanil, Date of authorisation: 25/06/2018, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): VeraSeal, human fibrinogen,human thrombin, Date of authorisation: 10/11/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): VeraSeal, human fibrinogen,human thrombin, Date of authorisation: 10/11/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Resolor, prucalopride, Date of authorisation: 14/10/2009, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Resolor, prucalopride, Date of authorisation: 14/10/2009, Revision: 30, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness